For the year ending 2025-12-31, APTN had $425,089 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -5,167,569 |
| Amortization of debt issuance costs and discounts | 53,722 |
| Change in fair value of derivative liabilities | 6,312 |
| Loss (gain) on extinguishment of debt | 326,345 |
| Shares issued in exchange for services | 250,000 |
| Stock-based compensation | 496,864 |
| Prepaid expenses and other current assets | 148,531 |
| Accounts payable- trade | 496,910 |
| Accrued expenses | -453,445 |
| Accrued interest | 14,190 |
| Net cash used in operating activities | -4,777,892 |
| Repayment of notes payable- related party | 275,000 |
| Proceeds from issuance of common stock and warrants in private placements | 7,161,504 |
| Payment of issuance costs related to private placements | 1,683,523 |
| Net cash provided by financing activities | 5,202,981 |
| Net increase in cash and cash equivalents | 425,089 |
| Cash and cash equivalents - beginning of year | 34,085 |
| Cash and cash equivalents - end of year | 459,174 |
ADAPTIN BIO, INC. (APTN)
ADAPTIN BIO, INC. (APTN)